Drug intelligence / Profile preview

neomycin + metronidazole

Development stage
Unknown
Lead developer
ACM Pharma Fonderephar
Modality
Small Molecules
Administration
Oral, Vaginal (in Some Formulations With Other Agents)[7]
01

Overview

Neomycin + metronidazole is a combination of two antibiotics used primarily for the reduction of colonic bacterial flora prior to elective colorectal surgery. Neomycin is an aminoglycoside antibiotic that acts by inhibiting protein synthesis in bacteria, mainly targeting aerobic Gram-negative organisms. Metronidazole is a nitroimidazole antibiotic effective against anaerobic bacteria and certain protozoa; it works by disrupting DNA synthesis in susceptible organisms. The combination is administered orally and has been shown to significantly reduce both aerobic and anaerobic bacterial counts in the colon, thereby lowering the risk of postoperative wound infections and sepsis following bowel surgery[1][4][6][8][9]. This regimen may also be used as part of preoperative prophylaxis protocols alongside mechanical bowel preparation.

Other names
Metronidazole and NeomycinNeomycin and Metronidazole
02

Targets

30S A-site (Bacterial ribosomal 30S A-site)bacterial dsDNA (Bacterial double-stranded DNA)

Beyond the preview

Go deeper on neomycin + metronidazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on neomycin + metronidazole.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call